We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. Patients refractory or intolerant to standard therapies received TAS-102 (30–35 mg/m2 twice daily on days 1–5 and days 8–12 every 28 days) plus bevacizumab 5 mg/kg on days 1 and 15. Clinical and pathological characteristics, overall response rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) data were collected and analysed. Thirty-five patients were treated from July 2019 to October 2021 (median age 64 years). The majority of patients (68.6%) were receiving TAS-102 plus bevacizumab as third-line treatment. Patients received a median of 4 (range 2–15) cycles of treatment. Among 31 patients evaluable for response (88.6%), ORR and DCR were 3.2% and 51.6%, respectively. After a median 11.6 months’ follow-up, median PFS was 4.3 (95% confidence interval [CI] 3.4–5.1) months and median OS was 9.3 (95% CI 6.6–12.1) months. The most common grade 3–4 toxicities were neutropenia, asthenia and nausea/vomiting, and there were no treatment-related deaths. This real-world study confirms the efficacy and safety of TAS-102 plus bevacizumab in patients with refractory mCRC.
BackgroundCeritinib is indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC), when the disease is advanced, the patient is anaplastic lymphoma kinase (ALK) positive and the disease has been treated previously with crizotinib. The data sheet for ceritinib describes hepatotoxicity as an uncommon adverse reaction observed in less than 1% of patients in clinical trials. In addition, ceritinib is on the European list of medicinal products under additional monitoring.PurposeTo describe a case of severe hepatotoxicity in a patient with advanced NSCLC treated with ceritinib.Material and methodsThis was a descriptive and retrospective clinical case. Data were obtained by review of the electronic medical records.ResultsA 57-year-old man was followed by the oncology service for an ALK positive advanced NSCLC. He had received treatment with crizotinib 250 mg twice a day from November 2015 to June 2016 when this treatment was interrupted because of disease progression which was determined by imaging tests.Consequently, ceritinib treatment was started in June 2016 with a daily dose of 750 mg. Before starting this medication, laboratory hepatic parameters were controlled (including AST, ALT and total bilirubin), as indicated in the data sheet, and all were in normal range. A month later, there was a marked elevation in transaminases: GPT 455 (grade 3), GOT 123 (grade 2), GGT 721, alkaline phosphatase 662. Ceritinib was discontinued and transaminases started to decrease. The Karch–Lasagna algorithm established a ‘probable’ relationship between hepatotoxicity and ceritinib based on temporal correlation of the facts and the apparent lack of another perpetrator of hepatic damage.ConclusionDrug induced hepatic injury is one of the most common reasons for withdrawal of an approved drug. For this reason, health professionals must be vigilant in identifying drug related liver injury, especially those related to drugs on the European list of medicinal products under additional monitoring. In our case, hepatic transaminases increased progressively throughout the course of the treatment with ceritinib and have continuously decreased since ceritinib discontinuation. This adverse reaction was reported to the national pharmacovigilance system.References and/or acknowledgementsEuropean list of medicinal products under additional monitoring. September 2016.No conflict of interest
excellent if £5%. From 2016 to 2019 an audit was carried out annually, selecting a random sample of 30 patients and establishing an annual improvement plan according to the results (Table 1).The improvement proposals established for each year were: 2016, include a week rotation in the reconciliation area for the first-year resident; 2017, extend MR rotation of the thirdyear resident from 2 to 5 months; 2018, establish a supervision/review circuit by the reference pharmacist of the RRs performed.
Background The Pharmacy and Haematology units, together with the hospital management, implemented a system for the dispensing of low molecular weight heparins (LMWH) for patients treated for anticoagulation with acenocoumarol and awaiting minor outpatient surgery. Purpose To evaluate the implementation of this protocol, and to quantify its financial impact. Materials and methods Retrospective observational study of 100% of the patients included in 2012. Data obtained: number of patients, demographic data and number of units LMWH dispensed. For the cost calculation, the differential cost was used between the acquisition cost and cost per prescription. We also took into account the number of units left over at home if the LMWH had been acquired by prescription. Results A total of 591 patients were included (mean age 71.83 ± 11.65). A total of 4,637 doses of LMWH were dispensed (mean 7.84 ± 1.98 days’ treatment per patient), all of which were accompanied by verbal and written information. Introducing this system simplified the acquisition of LMWH and reinforced the information given to the patients. It also streamlined the haematology consultations and avoided having to suspend scheduled surgery due to a failure to adhere to or understand the treatment. The new system saved 46,298 euros during the study period. The number of excess units if they had been acquired by prescription would have been 1,325 units. Dispensing the precise number of units helped to prevent possible medicines errors. Conclusions The new system ensures that patients understand their instructions and reinforces compliance, as well as providing significant savings for the healthcare authorities. The results of implementing this system reaffirm the validity of multidisciplinary working protocols of this kind in order to optimise available resources. No conflict of interest.
BackgroundLung cancer is the most common cancer worldwide as well as the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. Multiple advances in the staging, diagnostic procedures and therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5 year survival. Patients diagnosed with stage 4 NSCLC have poor survival rates (median 9–12 months).PurposeTo analyse and describe the clinical case of a long-term survival lung cancer patient.Material and methodsObservational retrospective clinical case. Data were obtained by review of the electronic medical records.ResultsA 46-years-old female followed by the oncology service for an advanced NSCLC anaplastic lymphoma kinase (ALK) positive EGFR wild-type. She received as first-line treatment crizotinib (250 mg, twice daily) from May 2013 until July 2015, when it was stopped by the disease’s progression, which was determined by imaging test. Crizotinib was well tolerated, and delays or interruptions were not necessary. In August 2015, she was involved in a clinical trial beginning treatment with AP26113 (brigatinib) 90 mg/24 hours 7 days and continuation with 180 mg/24 hours until June 2017, when it was interrupted by clinical progression. During this period, the drug was discontinued due to pneumonitis grade 1 (1–28 October 2015). She started treatment with lorlatinib (one daily 100 mg) until August 2017. In this period she suffered nail loss grade 1–2, with haemiparesis worsening and dysarthria increasing. In August, alectinib was authorised as a new line of treatment (fourth line). Currently, she continues with this treatment, presenting only dysgeusia grade 1.ConclusionActivating gene rearrangements in ALK have been identified as driver mutations in approximately 2% to 7% of patients with NSCLC. Although crizotinib is an effective treatment, some patients have a relatively short duration of response, and other patients fail to achieve a response. It is important to develop therapies that potentially can provide significant improvement in terms of treatment in ALK positive patients. In the case of this patient, there is a clear benefit of this type of therapy.Reference and/or Acknowledgements1. Clin Transl Oncol2015;17:1020–1029.No conflict of interest
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.